By Pam Harrison, Medscape
February 07, 2017 – Only a relatively small proportion of women with early-stage breast cancer receive genetic testing prior to surgery, despite the fact that the majority of such women would like to be tested, and many women would stand to benefit from knowing their mutation carrier status, a large, population-based study concludes. Among the women who are tested, many are not counseled as to what having a cancer-specific mutation might mean for their prognosis, it also found. The study was published online February 7, 2017 in JAMA.
SOURCE: Medscape; February 7, 2017; http://www.medscape.com/viewarticle/875471